What is the share price of Metropolis Healthcare Ltd (METROPOLIS) today?
The share price of METROPOLIS as on 5th December 2025 is ₹1925.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Metropolis Healthcare Ltd (METROPOLIS) share?
The past returns of Metropolis Healthcare Ltd (METROPOLIS) share are- Past 1 week: 0.29%
- Past 1 month: -3.51%
- Past 3 months: -13.66%
- Past 6 months: 13.98%
- Past 1 year: -8.26%
- Past 3 years: 30.60%
- Past 5 years: -3.21%
What are the peers or stocks similar to Metropolis Healthcare Ltd (METROPOLIS)?
The peers or stocks similar to Metropolis Healthcare Ltd (METROPOLIS) include:What is the market cap of Metropolis Healthcare Ltd (METROPOLIS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Metropolis Healthcare Ltd (METROPOLIS) is ₹10007.34 Cr as of 5th December 2025.What is the 52 week high and low of Metropolis Healthcare Ltd (METROPOLIS) share?
The 52-week high of Metropolis Healthcare Ltd (METROPOLIS) is ₹2263 and the 52-week low is ₹1315.What is the PE and PB ratio of Metropolis Healthcare Ltd (METROPOLIS) stock?
The P/E (price-to-earnings) ratio of Metropolis Healthcare Ltd (METROPOLIS) is 69.04. The P/B (price-to-book) ratio is 7.50.Which sector does Metropolis Healthcare Ltd (METROPOLIS) belong to?
Metropolis Healthcare Ltd (METROPOLIS) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Metropolis Healthcare Ltd (METROPOLIS) shares?
You can directly buy Metropolis Healthcare Ltd (METROPOLIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Metropolis Healthcare Ltd
METROPOLIS Share Price
1,925.900.27% (-5.20)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
METROPOLIS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
METROPOLIS Performance & Key Metrics
METROPOLIS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 63.25 | 7.50 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
78%
Analysts have suggested that investors can buy this stock
from 18 analysts
Price Upside
Earnings Growth
Rev. Growth
METROPOLIS Company Profile
Metropolis Healthcare is a medical laboratory operator
MAXHEALTH
PE Ratio
98.00
98.00
1Y Return
1.85%
1.85%
Buy Reco %
77.27
77.27
APOLLOHOSP
PE Ratio
71.61
71.61
1Y Return
0.43%
0.43%
Buy Reco %
86.21
86.21
FORTIS
PE Ratio
86.64
86.64
1Y Return
24.99%
24.99%
Buy Reco %
75.00
75.00
PE Ratio
49.80
49.80
1Y Return
47.18%
47.18%
Buy Reco %
77.78
77.78
ASTERDM
PE Ratio
6.28
6.28
1Y Return
34.87%
34.87%
Buy Reco %
100.00
100.00
METROPOLIS Sentiment Analysis
METROPOLIS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
METROPOLIS Stock Summary · November 2025
Metropolis Healthcare is on a robust growth trajectory, driven by a strategic focus on expanding its network and enhancing service quality, particularly in the diagnostics sector. The company plans to establish an additional 300 centers by year-end, capitalizing on the rising demand for preventive care and specialized testing, including opportunities in GLP-1 therapies. Despite facing challenges in integrating recent acquisitions and managing operational costs, Metropolis reported a 23% year-over-year revenue growth, supported by strong performances in both B2C and B2B segments. The integration of AI solutions and a commitment to operational efficiency are expected to bolster margins, while the consolidation trends in the industry present both challenges and opportunities for future profitability. Overall, the outlook remains positive, with management confident in achieving revenue and margin targets in the coming quarters.
METROPOLIS Stock Growth Drivers
METROPOLIS Stock Growth Drivers
7Strong Financial Performance
Metropolis Healthcare reported a year-over-year revenue growth of 23% for Q2 and H1 FY '26,
Operational Efficiency and Strategic Initiatives
The company has successfully implemented several digital initiatives, including a new consumer app and partner
METROPOLIS Stock Challenges
METROPOLIS Stock Challenges
6Revenue Growth Challenges
The company has reported a decrease in B2C revenue from 59% to 56% due to
Integration Difficulties
The integration of Core Diagnostics is facing challenges, particularly in cultural integration, which is expected
METROPOLIS Forecast
METROPOLIS Forecasts
Price
Revenue
Earnings
METROPOLIS Share Price Forecast
METROPOLIS Share Price Forecast
2025
Current
₹1,931.10
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,931.10
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
METROPOLIS Company Revenue Forecast
METROPOLIS Company Revenue Forecast
2025
Current
₹1.35
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.35
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
METROPOLIS Stock EPS (Earnings Per Share) Forecast
METROPOLIS Stock EPS (Earnings Per Share) Forecast
2025
Current
₹28.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹28.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
METROPOLIS
METROPOLIS
Income
Balance Sheet
Cash Flow
Annual Normal View
METROPOLIS Income Statement
METROPOLIS Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 570.31 | 654.93 | 769.39 | 864.98 | 1,010.04 | 1,261.96 | 1,163.43 | 1,216.83 | 1,346.31 | 1,501.24 | ||||||||||
Raw Materials | 135.10 | 145.90 | 173.51 | 204.14 | 252.16 | 276.02 | 253.26 | 242.57 | 268.68 | 1,151.04 | ||||||||||
| Power & Fuel Cost | 9.12 | 9.99 | 11.00 | 12.49 | 12.00 | 14.73 | 14.43 | 16.20 | 19.24 | |||||||||||
| Employee Cost | 127.70 | 147.37 | 176.21 | 190.16 | 198.64 | 233.17 | 252.73 | 275.78 | 313.75 | |||||||||||
| Selling & Administrative Expenses | 101.29 | 90.92 | 106.87 | 165.77 | 185.28 | 311.76 | 289.77 | 307.81 | 353.15 | |||||||||||
| Operating & Other expenses | 18.01 | 74.51 | 91.07 | 71.76 | 60.12 | 44.68 | 44.67 | 77.42 | 68.07 | |||||||||||
EBITDA | 179.09 | 186.24 | 210.73 | 220.66 | 301.84 | 381.60 | 308.57 | 297.05 | 323.42 | 350.20 | ||||||||||
| Depreciation/Amortization | 17.23 | 19.02 | 20.07 | 39.27 | 45.94 | 63.22 | 89.22 | 94.47 | 108.68 | 119.58 | ||||||||||
| PBIT | 161.86 | 167.22 | 190.66 | 181.39 | 255.90 | 318.38 | 219.35 | 202.58 | 214.74 | 230.62 | ||||||||||
| Interest & Other Items | 1.94 | 3.54 | 4.12 | 12.65 | 11.56 | 25.02 | 31.85 | 27.89 | 23.89 | 20.01 | ||||||||||
| PBT | 159.92 | 163.68 | 186.54 | 168.74 | 244.34 | 293.36 | 187.50 | 174.69 | 190.85 | 210.61 | ||||||||||
| Taxes & Other Items | 58.26 | 59.45 | 66.40 | 41.41 | 61.22 | 79.16 | 44.62 | 46.87 | 45.89 | 52.39 | ||||||||||
| Net Income | 101.66 | 104.23 | 120.14 | 127.33 | 183.12 | 214.20 | 142.88 | 127.82 | 144.96 | 158.22 | ||||||||||
| EPS | 20.48 | 21.00 | 24.07 | 25.26 | 36.00 | 41.88 | 27.91 | 24.96 | 28.14 | 30.54 | ||||||||||
| DPS | 10.07 | 0.00 | 13.26 | 8.00 | 8.00 | 8.00 | 8.00 | 4.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.49 | 0.00 | 0.55 | 0.32 | 0.22 | 0.19 | 0.29 | 0.16 | 0.00 | 0.00 |
METROPOLIS Company Updates
FY 2026FY 2026
Investor Presentation
Nov 4PDF
Aug 7PDF
METROPOLIS Stock Peers
METROPOLIS Past Performance & Peer Comparison
METROPOLIS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Metropolis Healthcare Ltd | 69.04 | 7.50 | — |
| Max Healthcare Institute Ltd | 98.00 | 11.24 | 0.14% |
| Apollo Hospitals Enterprise Ltd | 71.61 | 9.33 | 0.18% |
| Fortis Healthcare Ltd | 86.64 | 7.32 | 0.11% |
METROPOLIS Stock Price Comparison
Compare METROPOLIS with any stock or ETFCompare METROPOLIS with any stock or ETF
METROPOLIS
METROPOLIS Holdings
METROPOLIS Shareholdings
METROPOLIS Promoter Holdings Trend
METROPOLIS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
METROPOLIS Institutional Holdings Trend
METROPOLIS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
METROPOLIS Shareholding Pattern
METROPOLIS Shareholding Pattern
METROPOLIS Shareholding History
METROPOLIS Shareholding History
Foreign Institutions
Mutual Funds Invested in METROPOLIS
Mutual Funds Invested in METROPOLIS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Metropolis Healthcare Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.3472% | Percentage of the fund’s portfolio invested in the stock 1.33% | Change in the portfolio weight of the stock over the last 3 months -0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/34 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 3.1996% | Percentage of the fund’s portfolio invested in the stock 0.35% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/59 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.4534% | Percentage of the fund’s portfolio invested in the stock 1.36% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/85 (-4) |
Compare 3-month MF holding change on Screener
smallcases containing METROPOLIS stock
smallcases containing METROPOLIS stock
Looks like this stock is not in any smallcase yet.
METROPOLIS Events
METROPOLIS Events
METROPOLIS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
METROPOLIS Dividend Trend
No dividend trend available
METROPOLIS Upcoming Dividends
METROPOLIS Upcoming Dividends
No upcoming dividends are available
METROPOLIS Past Dividends
METROPOLIS Past Dividends
Cash Dividend
Ex DateEx DateNov 11, 2025
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 11, 2025
Cash Dividend
Ex DateEx DateNov 17, 2023
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 17, 2023
Cash Dividend
Ex DateEx DateFeb 23, 2023
Interim
Interim | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Feb 23, 2023
Cash Dividend
Ex DateEx DateFeb 21, 2022
Interim
Interim | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Feb 21, 2022
Cash Dividend
Ex DateEx DateFeb 17, 2021
Interim
Interim | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Feb 17, 2021
METROPOLIS Stock News & Opinions
METROPOLIS Stock News & Opinions
Articles & Videos
Earnings
Metropolis Healthcare consolidated net profit rises 13.22% in the September 2025 quarter
Net profit of Metropolis Healthcare rose 13.22% to Rs 52.67 crore in the quarter ended September 2025 as against Rs 46.52 crore during the previous quarter ended September 2024. Sales rose 22.70% to Rs 429.19 crore in the quarter ended September 2025 as against Rs 349.79 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales429.19349.79 23 OPM %25.2225.70 - PBDT103.4388.21 17 PBT71.0361.40 16 NP52.6746.52 13 Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Board of Metropolis Healthcare recommends interim dividend
Metropolis Healthcare announced that the Board of Directors of the Company at its meeting held on 4 November 2025, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 200%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Earnings
Metropolis Healthcare standalone net profit rises 10.34% in the September 2025 quarter
Net profit of Metropolis Healthcare rose 10.34% to Rs 46.63 crore in the quarter ended September 2025 as against Rs 42.26 crore during the previous quarter ended September 2024. Sales rose 10.62% to Rs 355.71 crore in the quarter ended September 2025 as against Rs 321.57 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales355.71321.57 11 OPM %25.6825.51 - PBDT89.9080.88 11 PBT62.1154.87 13 NP46.6342.26 10 Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Metropolis Healthcare to discuss results
Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 4 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Metropolis Healthcare allots 14,522 equity shares under ESOP
Metropolis Healthcare has allotted 14,522 equity shares under ESOP on 12 October 2025. With this, the paid up equity share capital has increased to Rs 10,36,43,964. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Metropolis Healthcare jumps on strong Q2 biz update
The revenue growth includes contributions from Core Diagnostics, Scientific Pathology (Scientific), Agra and Dr. Ahuja's Pathology & Imaging Center (DAPIC), Dehradun. The TruHealth Wellness and Specialty segments posted YoY growth of about 25% and 36%, respectively, in Q2FY26. B2C revenues registered a YoY growth of around 16%, while B2B revenues grew approximately 34% driven by higher contribution of B2B business in core diagnostics. During the quarter, the company acquired Dr. RS Patil's Ambika Pathology Laboratory, Kolhapur (Ambika Pathology), effective September 18, 2025. This acquisition strengthens the company's leadership position in the Kolhapur region and is strategically aimed at establishing a mini reference laboratory to serve the surrounding 4'5 districts in the Western Maharashtra belt aiming to boost productivity, increase throughput, and reduce turnaround time (TAT). On a consolidated basis, the company is debt free and has net cash surplus of around Rs 55 crore. On standalone basis, the company's revenue grew by approximately 12% YoY, driven by an increase in patient and test volumes, a favorable shift in product mix, and improved realizations. EBITDA margins for the current quarter saw a QoQ improvement, reflecting resilient business operations and strong operating leverage inherent in the business model. Margins also showed a positive year-on-year trend. Metropolis Healthcare provides diagnostic services to patients, healthcare providers, and corporates across India and Africa. It offers a comprehensive range of more than 4,100 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company's consolidated net profit jumped 18.7% to Rs 45.06 crore on 23.2% increase in net sales to Rs 386.06 crore in Q1 FY26 over Q1 FY25.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Metropolis Healthcare acquires Kolhapur-based Ambika Pathology
Metropolis Healthcare announced the completion of its fourth acquisition in the last 10 months, with Dr. R.S. Patil's Ambika Pathology Laboratory (Ambika Pathology) in Kolhapur joining the Metropolis network.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Metropolis Healthcare incorporates WoS - Metropolis Quality Solutions
Metropolis Healthcare has incorporated a wholly owned subsidiary named, Metropolis Quality Solutions on 15 September 2025. Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Metropolis Healthcare gains after incorporating new subsidiary
The newly formed entity will carry out the business of developing and dealing in technology driven products and services in the healthcare sector. The company has subscribed 10,000 equity shares of the subsidiary, with a face value of Rs 10 each. Metropolis Healthcare provides diagnostic services to patients, healthcare providers, and corporates across India and Africa. It offers a comprehensive range of more than 4,100 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company's consolidated net profit jumped 18.7% to Rs 45.06 crore on 23.2% increase in net sales to Rs 386.06 crore in Q1 FY26 over Q1 FY25.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Metropolis Healthcare consolidated net profit rises 18.74% in the June 2025 quarter
Net profit of Metropolis Healthcare rose 18.74% to Rs 45.06 crore in the quarter ended June 2025 as against Rs 37.95 crore during the previous quarter ended June 2024. Sales rose 23.20% to Rs 386.06 crore in the quarter ended June 2025 as against Rs 313.36 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales386.06313.36 23 OPM %23.2525.15 - PBDT92.0876.62 20 PBT61.2351.08 20 NP45.0637.95 19 Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.25%, vs industry avg of 13.4%
Over the last 5 years, market share decreased from 2.08% to 1.69%
Over the last 5 years, net income has grown at a yearly rate of 2.63%, vs industry avg of 42.46%